Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04819100 · ClinicalTrials.gov registry record · Phase 3

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
152
Enrollment target
20
Study locations

NCT04819100: Active Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.

NCT04819100 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 152 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04819100, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.

Primary Outcome

EFS by Investigator Assessment in the Primary Analysis Population

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Placebo
  • DRUG Selpercatinib

Study Locations (20)

California

  • UCLA Hematology/Oncology - Santa Monica - Los Angeles
  • Stockton Hematology Oncology Group - Stockton
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance

Florida

  • GenesisCare - Aventura
  • GenesisCare - Boca Raton - Boca Raton
  • USO-Cancer Care Center of Brevard, Inc. - Palm Bay

Queensland

  • Sunshine Coast University Hospital - Birtinya
  • Rockhampton Hospital - Rockhampton
  • The Townsville Hospital - Townsville

New York

  • USO-New York Oncology Hematology, P.C - Latham
  • Memorial Sloan Kettering Cancer Center - New York

Tennessee

  • Sarah Cannon Research Institute SCRI - Nashville
  • Tennessee Oncology Nashville - Nashville

Texas

  • USO-Texas Oncology-Central/South Texas - Austin
  • US Oncology - The Woodlands

Victoria

  • Ballarat Health Services - Ballarat Central
  • Bendigo Health Care Group - Bendigo

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2021-12-20
Est. Completion 2028-05
Phase Phase 3
Eli Lilly and Company

1,341 total trials

What the registry record for NCT04819100 still lists

NCT04819100 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04819100 names 20 study sites across 10 states, led by California, Florida, Queensland.

Frequently Asked Questions

What is clinical trial NCT04819100 about?

NCT04819100 is a clinical study titled "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)". The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop ...

What is the current status of trial NCT04819100?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2021-12-20. Estimated completion is 2028-05.

What conditions does trial NCT04819100 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT04819100?

The interventions under investigation include: Placebo (DRUG), Selpercatinib (DRUG).

Who is sponsoring clinical trial NCT04819100?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04819100 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04819100's enrollment target sits among peer trials

152 57th of 130 higher than 74 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03328078 · 152 participants · Phase 1

    CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • NCT04458532 · 152 participants · NA

    Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

  • NCT04858334 · 152 participants · Phase 2

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  • NCT04993859 · 152 participants

    Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04819100, the US trial registry maintained by the National Library of Medicine. NCT04819100 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.